Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 200 of 375 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/11
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 04/30/16
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 07/31/14
End: 07/31/24
Due: 07/31/25
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 08/31/15
Due: 08/31/16
Phase: N/A
Priority: Normal
Start: 10/05/23
End: 03/10/24
Due: 03/10/25
Phase: N/A
Priority: Normal
Start: 06/03/20
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 02/26/21
End: 05/26/24
Due: 05/26/25
Phase: N/A
Priority: Normal
Start: 12/29/21
End: 04/30/22
Due: 04/30/23
Phase: N/A
Priority: Normal
Start: 05/31/11
End: 09/30/11
Due: 09/30/12
Phase: N/A
Priority: Normal
Start: 04/10/19
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 10/20/18
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 12/31/17
Due: 12/31/18
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 09/30/16
Due: 09/30/17
Phase: N/A
Priority: Normal
Start: 04/12/21
End: 06/12/21
Due: 06/12/22
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Phase: N/A
Priority: Normal
Start: 05/02/17
End: 05/02/20
Due: 05/02/21
Phase: N/A
Priority: Normal
Start: 04/10/17
End: 04/30/20
Due: 04/30/21
Phase: N/A
Priority: Normal
Start: 12/01/22
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 01/03/18
End: 01/03/23
Due: 01/03/24
Phase: N/A
Priority: Normal
Start: 08/01/17
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 07/31/15
Due: 07/31/16
Phase: N/A
Priority: Normal
Start: 06/30/12
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 03/31/16
End: 01/31/18
Due: 01/31/19
Phase: N/A
Priority: Normal
Start: 09/08/22
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 05/10/19
End: 04/30/23
Due: 04/30/24